Sign In
Buy TLSA
$1.03
+0.0600 (+6.19%)
At Close: Jul 31, 2026
Tiziana Life Sciences expands Phase 2 MS trial to fifth site, commences patient dosing
11:03am, Friday, 13'th Jun 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that it has initiated patient dosing at the Weill Cornell Medicine Multiple Sclerosis Center in New York City as part of its ongoing Phase 2 clinical
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences to Present at the Bio International Convention
08:30am, Friday, 13'th Jun 2025
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease
07:00am, Friday, 23'rd May 2025
NEW YORK, May 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows
09:43am, Thursday, 15'th May 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA)' investigational therapy intranasal foralumab has been shown to significantly reduce neuroinflammation in a 78-year-old patient with moderate Alzheimer's diseas
Tiziana Life Sciences Announces Purchase of Shares by Chairman
07:00am, Monday, 12'th May 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies wi
Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab
09:31am, Friday, 09'th May 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said on Friday that a patient with moderate Alzheimer's disease showed a marked reduction in brain inflammation after three months of treatment with its lead dr
NEW YORK, May 09, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies w
Tiziana shares surge 21% on promising multiple sclerosis data
10:57am, Tuesday, 06'th May 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) shares jumped 21% in early trading Tuesday after the company reported positive early-stage data for its experimental multiple sclerosis treatment, nasal foralu
Tiziana reports encouraging results for nasal MS drug in early study
08:27am, Tuesday, 06'th May 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) said Tuesday that its experimental multiple sclerosis therapy, nasal foralumab, showed positive results in an early-stage study, with patients experiencing stab
Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis
07:00am, Tuesday, 06'th May 2025
Meaningful Fatigue score reduction seen in study is a critically important quality of life (QoL) measure for Multiple Sclerosis patients. All patients experienced stabilization of Expanded Disability
Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts
08:38am, Wednesday, 23'rd Apr 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) announced that the University of Massachusetts has commenced dosing patients in its ongoing Phase 2 trial of its lead candidate intranasal foralumab, a fully hu
Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial
07:00am, Wednesday, 23'rd Apr 2025
NEW YORK, April 23, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
09:04am, Wednesday, 02'nd Apr 2025
Tiziana Life Sciences Ltd (NASDAQ:TLSA) has announced that Johns Hopkins University has begun dosing patients in its Phase 2 clinical trial evaluating intranasal foralumab for non-active Secondary Pro
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
08:00am, Wednesday, 02'nd Apr 2025
NEW YORK, April 02, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies
